Imaging Technologies for Cerebral Pharmacokinetic Studies: Progress and Perspectives

Abstract

Pharmacokinetic assessment of drug disposition processes in vivo is critical in predicting pharmacodynamics and toxicology to reduce the risk of inappropriate drug development. The blood–brain barrier (BBB), a special physiological structure in brain tissue, hinders the entry of targeted drugs into the central nervous system (CNS), making the drug concentrations in target tissue correlate poorly with the blood drug concentrations. Additionally, once non-CNS drugs act directly on the fragile and important brain tissue, they may produce extra-therapeutic effects that may impair CNS function. Thus, an intracerebral pharmacokinetic study was developed to reflect the disposition and course of action of drugs following intracerebral absorption. Through an increasing understanding of the fine structure in the brain and the rapid development of analytical techniques, cerebral pharmacokinetic techniques have developed into non-invasive imaging techniques. Through non-invasive imaging techniques, molecules can be tracked and visualized in the entire BBB, visualizing how they enter the BBB, allowing quantitative tools to be combined with the imaging system to derive reliable pharmacokinetic profiles. The advent of imaging-based pharmacokinetic techniques in the brain has made the field of intracerebral pharmacokinetics more complete and reliable, paving the way for elucidating the dynamics of drug action in the brain and predicting its course. The paper reviews the development and application of imaging technologies for cerebral pharmacokinetic study, represented by optical imaging, radiographic autoradiography, radionuclide imaging and mass spectrometry imaging, and objectively evaluates the advantages and limitations of these methods for predicting the pharmacodynamic and toxic effects of drugs in brain tissues.

Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders

“…To establish the proof of efficacy, pharmacokinetic profiling on a radioactive drug [ 199 ] in animal species to demonstrate preferred accumulation in the brain is a well-defined technique; the process involves making the current product radioactive and conjugating it with transferrin in vitro and then comparing the radio image with the same molecule but without conjugation. Importantly, these studies can be executed swiftly and with minimal costs without requiring regulatory oversight.…”

Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody–Transferrin Conjugates

“…To establish the proof of efficacy, as suggested above, a pharmacokinetic analysis based on a radioactive drug [99] in animal species should suffice; the process involves making the current product radioactive and conjugating it with transferrin first in vitro, comparing the radio image with the same molecule but without conjugation, before transforming the process to mRNA. Since these studies do not involve humans, they can be conducted without regulatory involvement within a very short time [100] and with almost negligible cost.…”